Cargando…
Prognostic Significance of Pretreatment Staging With (18)F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study
Without the routine use of (18)F-FDG PET for initial staging of esophageal cancer, it may lead to inaccurate staging and suboptimal treatment. The purpose of this study was to evaluate the prognostic significance of pretreatment (18)F-FDG PET in nonmetastatic esophageal cancer by comparing the survi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257472/ https://www.ncbi.nlm.nih.gov/pubmed/34034334 http://dx.doi.org/10.1097/RLU.0000000000003739 |
_version_ | 1783718321636507648 |
---|---|
author | Lu, Hsi-Huei Chiu, Nan-Ching Tsai, Mu-Hung |
author_facet | Lu, Hsi-Huei Chiu, Nan-Ching Tsai, Mu-Hung |
author_sort | Lu, Hsi-Huei |
collection | PubMed |
description | Without the routine use of (18)F-FDG PET for initial staging of esophageal cancer, it may lead to inaccurate staging and suboptimal treatment. The purpose of this study was to evaluate the prognostic significance of pretreatment (18)F-FDG PET in nonmetastatic esophageal cancer by comparing the survival between patients with and without pretreatment PET. MATERIALS AND METHODS: We selected newly diagnosed esophageal cancer patients without metastasis between 2009 and 2015 from Taiwan Cancer Registry and National Health Insurance Research Database. Pretreatment (18)F-FDG PET staging was determined according to the implementation of PET within 90 days before starting treatment. Overall survival was calculated from the day of treatment initiation to the death from any cause. Survival curves were compared between patients with and without PET staging using the log-rank test. RESULTS: Of the 9078 patients included, 1765 (19.4%) and 7313 (80.6%) patients were staged with and without pretreatment PET, respectively. The median follow-up time for all patients and survivors was 1.29 years and 5.46 years, respectively. The pretreatment PET group had a lower risk of death than the no pretreatment PET group (hazards ratio, 0.74; 95% confidence interval, 0.70–0.79; P < 0.001). After adjusting for age, stage, histology, and tumor location, pretreatment PET remained significantly correlated with a lower risk of death (hazards ratio, 0.78; 95% confidence interval, 0.73–0.83; P < 0.001). CONCLUSIONS: The utilization of pretreatment (18)F-FDG PET for staging in nonmetastatic esophageal malignancy is associated with a lower risk of death even after adjusting for age, stage, histology, and tumor location. |
format | Online Article Text |
id | pubmed-8257472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-82574722021-07-08 Prognostic Significance of Pretreatment Staging With (18)F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study Lu, Hsi-Huei Chiu, Nan-Ching Tsai, Mu-Hung Clin Nucl Med Original Articles Without the routine use of (18)F-FDG PET for initial staging of esophageal cancer, it may lead to inaccurate staging and suboptimal treatment. The purpose of this study was to evaluate the prognostic significance of pretreatment (18)F-FDG PET in nonmetastatic esophageal cancer by comparing the survival between patients with and without pretreatment PET. MATERIALS AND METHODS: We selected newly diagnosed esophageal cancer patients without metastasis between 2009 and 2015 from Taiwan Cancer Registry and National Health Insurance Research Database. Pretreatment (18)F-FDG PET staging was determined according to the implementation of PET within 90 days before starting treatment. Overall survival was calculated from the day of treatment initiation to the death from any cause. Survival curves were compared between patients with and without PET staging using the log-rank test. RESULTS: Of the 9078 patients included, 1765 (19.4%) and 7313 (80.6%) patients were staged with and without pretreatment PET, respectively. The median follow-up time for all patients and survivors was 1.29 years and 5.46 years, respectively. The pretreatment PET group had a lower risk of death than the no pretreatment PET group (hazards ratio, 0.74; 95% confidence interval, 0.70–0.79; P < 0.001). After adjusting for age, stage, histology, and tumor location, pretreatment PET remained significantly correlated with a lower risk of death (hazards ratio, 0.78; 95% confidence interval, 0.73–0.83; P < 0.001). CONCLUSIONS: The utilization of pretreatment (18)F-FDG PET for staging in nonmetastatic esophageal malignancy is associated with a lower risk of death even after adjusting for age, stage, histology, and tumor location. Lippincott Williams & Wilkins 2021-08 2021-05-25 /pmc/articles/PMC8257472/ /pubmed/34034334 http://dx.doi.org/10.1097/RLU.0000000000003739 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Articles Lu, Hsi-Huei Chiu, Nan-Ching Tsai, Mu-Hung Prognostic Significance of Pretreatment Staging With (18)F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study |
title | Prognostic Significance of Pretreatment Staging With (18)F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study |
title_full | Prognostic Significance of Pretreatment Staging With (18)F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study |
title_fullStr | Prognostic Significance of Pretreatment Staging With (18)F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study |
title_full_unstemmed | Prognostic Significance of Pretreatment Staging With (18)F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study |
title_short | Prognostic Significance of Pretreatment Staging With (18)F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study |
title_sort | prognostic significance of pretreatment staging with (18)f-fdg pet in esophageal cancer: a nationwide population-based study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257472/ https://www.ncbi.nlm.nih.gov/pubmed/34034334 http://dx.doi.org/10.1097/RLU.0000000000003739 |
work_keys_str_mv | AT luhsihuei prognosticsignificanceofpretreatmentstagingwith18ffdgpetinesophagealcanceranationwidepopulationbasedstudy AT chiunanching prognosticsignificanceofpretreatmentstagingwith18ffdgpetinesophagealcanceranationwidepopulationbasedstudy AT tsaimuhung prognosticsignificanceofpretreatmentstagingwith18ffdgpetinesophagealcanceranationwidepopulationbasedstudy |